2nd Annual China’s Position in Global Manufacturing: A Comparison of China’s Emerging Position vs Established Regions’ Manufacturing Capacity and Production
An in-depth review of emerging trends and opportunities, with comparative data from BioPlan’s 20th Annual Report and Survey of Biopharmaceutical Manufacturing.
This analysis will help decision makers understand the changing China biopharmaceutical industry to make strategic decisions on why and when they should enter the China market.
Highlights and Table of Contents – In this analysis, we cover the following areas, based on data from the BioPlan 20th Annual Report:
Single Biomanufacturing Trend of 2023: What is the SINGLE most important biomanufacturing trend/operational area the industry must focus efforts on in 2023?
Novel Bioprocessing System To Test: Which novel bioprocessing systems or innovations do you plan to evaluate or test within your facility/company in the next 12 months? [Select all that apply]
Average Cost For Recombinant Protein: What is your AVERAGE cost per gram for your Facility’s PRIMARY Recombinant Protein manufactured at your facility ($USD)? (For Protein/mAb, not finished product)
Titer Range: Approximately, what range of titers are you currently obtaining for each of the following?
Current Percent of Total Capacity for Facility Operation, by Production System: Consider your facility’s total capacity, and the current “percent of capacity”.
Capacity Constraints: To what extent do you believe your facility is experiencing production capacity constraints today?
Downstream Bioprocessing Steps Creating Overall Capacity Constraints: Describe the extent to which your purification/chromatography steps create OVERALL capacity constraints at your facility?
Important Areas to Address for Industry to Avoid Significant Capacity Constraints: If this industry is to avoid significant capacity constraints, the most important areas to be addressed today are?
Budget and Funding Percentage Changes Over the Next 12 Months: By about what percent do you believe your BUDGET and FUNDING will change for each of the following over the next 12 months?
Actions to Reduce Overall Bioprocessing Costs During the Past 12 Months: During the past 12 months, which actions has your facility undertaken to reduce overall costs?
Single-use/disposable Biomanufacturing Systems: About what percent of your biomanufacturing systems (e.g., # of major components/devices) would you describe as ‘single-use’ or disposable?
Change in Spending on OUTSOURCING for R&D or Manufacturing in the Next 12 Months: How will your spending on OUTSOURCING of R&D or manufacturing change in the next 12 months?
Outsourcing Activities: How much outsourcing of the following activities is done by your facility today?
Top 3 New Bioprocessing Expenditures For Suppliers: In which new areas were your facility’s top 3 NEW bioprocessing expenditures in the past year?
This analysis will help decision makers understand the changing China biopharmaceutical industry to make strategic decisions on why and when they should enter the China market.
Highlights and Table of Contents – In this analysis, we cover the following areas, based on data from the BioPlan 20th Annual Report:
Single Biomanufacturing Trend of 2023: What is the SINGLE most important biomanufacturing trend/operational area the industry must focus efforts on in 2023?
Novel Bioprocessing System To Test: Which novel bioprocessing systems or innovations do you plan to evaluate or test within your facility/company in the next 12 months? [Select all that apply]
Average Cost For Recombinant Protein: What is your AVERAGE cost per gram for your Facility’s PRIMARY Recombinant Protein manufactured at your facility ($USD)? (For Protein/mAb, not finished product)
Titer Range: Approximately, what range of titers are you currently obtaining for each of the following?
Current Percent of Total Capacity for Facility Operation, by Production System: Consider your facility’s total capacity, and the current “percent of capacity”.
Capacity Constraints: To what extent do you believe your facility is experiencing production capacity constraints today?
Downstream Bioprocessing Steps Creating Overall Capacity Constraints: Describe the extent to which your purification/chromatography steps create OVERALL capacity constraints at your facility?
Important Areas to Address for Industry to Avoid Significant Capacity Constraints: If this industry is to avoid significant capacity constraints, the most important areas to be addressed today are?
Budget and Funding Percentage Changes Over the Next 12 Months: By about what percent do you believe your BUDGET and FUNDING will change for each of the following over the next 12 months?
Actions to Reduce Overall Bioprocessing Costs During the Past 12 Months: During the past 12 months, which actions has your facility undertaken to reduce overall costs?
Single-use/disposable Biomanufacturing Systems: About what percent of your biomanufacturing systems (e.g., # of major components/devices) would you describe as ‘single-use’ or disposable?
Change in Spending on OUTSOURCING for R&D or Manufacturing in the Next 12 Months: How will your spending on OUTSOURCING of R&D or manufacturing change in the next 12 months?
Outsourcing Activities: How much outsourcing of the following activities is done by your facility today?
Top 3 New Bioprocessing Expenditures For Suppliers: In which new areas were your facility’s top 3 NEW bioprocessing expenditures in the past year?
INTRODUCTION
RESEARCH METHODOLOGY
1 - SINGLE MOST IMPORTANT BIOMANUFACTURING TREND/OPERATIONAL AREA INDUSTRY MUST FOCUS EFFORTS FOR 2023
2 - NOVEL BIOPROCESSING SYSTEMS/INNOVATIONS FACILITIES PLAN TO EVALUATE IN THE NEXT 12 MONTHS
3 - AVERAGE COST FOR FACILITY’S PRIMARY RECOMBINANT PROTEIN MANUFACTURED AT FACILITY (PER GRAM)
4 - RANGE AND AVERAGES OF TITERS FOR MABS OBTAINED AT VARIOUS PRODUCTION SCALES
5 - CURRENT PERCENT OF TOTAL CAPACITY FOR FACILITY OPERATION, BY PRODUCTION SYSTEM
6 - PRODUCTION CAPACITY CONSTRAINTS FOR FACILITIES TODAY
7 - DOWNSTREAM BIOPROCESSING STEPS CREATING OVERALL CAPACITY CONSTRAINTS
8 - AREAS TO ADDRESS FOR INDUSTRY TO AVOID SIGNIFICANT CAPACITY CONSTRAINTS
9 - BUDGET AND FUNDING PERCENTAGE CHANGES OVER THE NEXT 12 MONTHS
10 - ACTIONS TO REDUCE OVERALL BIOPROCESSING COSTS DURING THE PAST 12 MONTHS
11 - PERCENTAGE OF FACILITIES’ UNIT OPERATIONS THAT ARE “SINGLE-USE OR DISPOSABLE”
12 - CHANGE IN SPENDING ON OUTSOURCING FOR R&D OR MANUFACTURING IN THE NEXT 12 MONTHS
13 - CURRENT OUTSOURCING FOR THE FOLLOWING ACTIVITIES BY FACILITIES
14 - TOP NEW BIOPROCESSING EXPENDITURES IN THE PAST YEAR
RESEARCH METHODOLOGY
1 - SINGLE MOST IMPORTANT BIOMANUFACTURING TREND/OPERATIONAL AREA INDUSTRY MUST FOCUS EFFORTS FOR 2023
2 - NOVEL BIOPROCESSING SYSTEMS/INNOVATIONS FACILITIES PLAN TO EVALUATE IN THE NEXT 12 MONTHS
3 - AVERAGE COST FOR FACILITY’S PRIMARY RECOMBINANT PROTEIN MANUFACTURED AT FACILITY (PER GRAM)
4 - RANGE AND AVERAGES OF TITERS FOR MABS OBTAINED AT VARIOUS PRODUCTION SCALES
5 - CURRENT PERCENT OF TOTAL CAPACITY FOR FACILITY OPERATION, BY PRODUCTION SYSTEM
6 - PRODUCTION CAPACITY CONSTRAINTS FOR FACILITIES TODAY
7 - DOWNSTREAM BIOPROCESSING STEPS CREATING OVERALL CAPACITY CONSTRAINTS
8 - AREAS TO ADDRESS FOR INDUSTRY TO AVOID SIGNIFICANT CAPACITY CONSTRAINTS
9 - BUDGET AND FUNDING PERCENTAGE CHANGES OVER THE NEXT 12 MONTHS
10 - ACTIONS TO REDUCE OVERALL BIOPROCESSING COSTS DURING THE PAST 12 MONTHS
11 - PERCENTAGE OF FACILITIES’ UNIT OPERATIONS THAT ARE “SINGLE-USE OR DISPOSABLE”
12 - CHANGE IN SPENDING ON OUTSOURCING FOR R&D OR MANUFACTURING IN THE NEXT 12 MONTHS
13 - CURRENT OUTSOURCING FOR THE FOLLOWING ACTIVITIES BY FACILITIES
14 - TOP NEW BIOPROCESSING EXPENDITURES IN THE PAST YEAR
FIGURES AND TABLES
Fig 1: Single Most Important Biomanufacturing Trend or Operational Area Industry Must Focus Efforts (China, US, W. Europe and ROW)
Fig 2: Single Most Important Biomanufacturing Trend or Operational Area Industry Must Focus Efforts (2022-2023)
Fig 3: Novel Bioprocessing Systems/Innovations to Evaluation in Next 12 Months (Global)
Fig 4: Average Cost per Gram for PRIMARY Recombinant Protein (by region, 2022 – 2023)
Fig 5: Range of mAb Titers Obtained at Various Production Scales, Distribution (China)
Fig 6: Average mAb Titer Obtained at the Following Production Scales (China), 2023 vs. 2022
Fig 7: Average mAb Titer Obtained at the Following Production Scales (Global), 2023
Fig 8: Average Production as % of Operating Capacity, By System (Global),
Fig 9: Capacity Utilization, By System (China), 2023 vs. 2022
Fig 10: Capacity Constraints, by Stage of Production (China), 2023
Fig 11: Capacity Constraints in Commercial Manufacturing (China), 2023 vs. 2022
Fig 12: Capacity Constraints in Commercial Manufacturing (Global), 2023
Fig 13: Impact on Capacity of Depth, Chromatography and UF Purification Steps (China), 2023
Fig 14: Impact on Capacity of Depth, Chromatography and UF Purification Steps, 'Severe or Significant' (China), 2023 vs. 2022
Fig 15: Comparative Impact on Capacity of Downstream Purification Steps, “Severe or Significant” (Global), 2023
Fig 16: Key Areas to Address to Avoid Capacity Constraints (Global), 2023
Fig 17: Percent Expecting “Some” Increase in Budgets for 2023 (Global)
Fig 18: Approximate Average Change in Biomanufacturers' Budgets (China), 2023 vs. 2022
Fig 19: Approximate Average Change in Biomanufacturers’ Budgets (Global), 2023
Fig 20: Cost-Cutting Changes: Actions Undertaken During 'Past 12 Months' (Global), 2023
Fig 21: Cost-Cutting Changes, Outsourced Jobs, by Segment, and Geography (Global), 2023
Fig 22: Cost-Cutting Changes, Outsourced Jobs, by Segment, and Geography (China), 2023 vs. 2022
Fig 23: Estimated Percentage of Facilities’ Unit Operations that are “Single-Use or Disposable” (Global), 2023
Fig 24: Estimated Percentage of Facilities’ Unit Operations that are 'Single-Use or Disposable' (China), 2023 vs. 2022
Fig 25: Change in Spending on Outsourcing for R&D or Manufacturing in Next 12 Months (Global), 2023
Fig 26: Change in Spending on Outsourcing for R&D or Manufacturing in Next 12 Months (China), 2023 vs. 2022
Fig 27: Percent of Biomanufacturers Outsourcing at Least Some Activity Today (Global), 2023
Fig 28: Estimated Average Percentage of Activity Outsourced by Facilities, (Global), 2023
Fig 29: Estimated Average Percentage of Activity Outsourced, by Facilities Today, Top 10, (China), 2023 vs. 2022
Fig 30: Top 3 New Bioprocessing Expenditure Focus Areas for Facilities (Global), 2023
Fig 31: Top 3 New Bioprocessing Expenditure Focus Areas for Facilities (China), 2023 vs. 2022
Fig 1: Single Most Important Biomanufacturing Trend or Operational Area Industry Must Focus Efforts (China, US, W. Europe and ROW)
Fig 2: Single Most Important Biomanufacturing Trend or Operational Area Industry Must Focus Efforts (2022-2023)
Fig 3: Novel Bioprocessing Systems/Innovations to Evaluation in Next 12 Months (Global)
Fig 4: Average Cost per Gram for PRIMARY Recombinant Protein (by region, 2022 – 2023)
Fig 5: Range of mAb Titers Obtained at Various Production Scales, Distribution (China)
Fig 6: Average mAb Titer Obtained at the Following Production Scales (China), 2023 vs. 2022
Fig 7: Average mAb Titer Obtained at the Following Production Scales (Global), 2023
Fig 8: Average Production as % of Operating Capacity, By System (Global),
Fig 9: Capacity Utilization, By System (China), 2023 vs. 2022
Fig 10: Capacity Constraints, by Stage of Production (China), 2023
Fig 11: Capacity Constraints in Commercial Manufacturing (China), 2023 vs. 2022
Fig 12: Capacity Constraints in Commercial Manufacturing (Global), 2023
Fig 13: Impact on Capacity of Depth, Chromatography and UF Purification Steps (China), 2023
Fig 14: Impact on Capacity of Depth, Chromatography and UF Purification Steps, 'Severe or Significant' (China), 2023 vs. 2022
Fig 15: Comparative Impact on Capacity of Downstream Purification Steps, “Severe or Significant” (Global), 2023
Fig 16: Key Areas to Address to Avoid Capacity Constraints (Global), 2023
Fig 17: Percent Expecting “Some” Increase in Budgets for 2023 (Global)
Fig 18: Approximate Average Change in Biomanufacturers' Budgets (China), 2023 vs. 2022
Fig 19: Approximate Average Change in Biomanufacturers’ Budgets (Global), 2023
Fig 20: Cost-Cutting Changes: Actions Undertaken During 'Past 12 Months' (Global), 2023
Fig 21: Cost-Cutting Changes, Outsourced Jobs, by Segment, and Geography (Global), 2023
Fig 22: Cost-Cutting Changes, Outsourced Jobs, by Segment, and Geography (China), 2023 vs. 2022
Fig 23: Estimated Percentage of Facilities’ Unit Operations that are “Single-Use or Disposable” (Global), 2023
Fig 24: Estimated Percentage of Facilities’ Unit Operations that are 'Single-Use or Disposable' (China), 2023 vs. 2022
Fig 25: Change in Spending on Outsourcing for R&D or Manufacturing in Next 12 Months (Global), 2023
Fig 26: Change in Spending on Outsourcing for R&D or Manufacturing in Next 12 Months (China), 2023 vs. 2022
Fig 27: Percent of Biomanufacturers Outsourcing at Least Some Activity Today (Global), 2023
Fig 28: Estimated Average Percentage of Activity Outsourced by Facilities, (Global), 2023
Fig 29: Estimated Average Percentage of Activity Outsourced, by Facilities Today, Top 10, (China), 2023 vs. 2022
Fig 30: Top 3 New Bioprocessing Expenditure Focus Areas for Facilities (Global), 2023
Fig 31: Top 3 New Bioprocessing Expenditure Focus Areas for Facilities (China), 2023 vs. 2022
